Skip to main content
Caplight Logo









neuro42

neuro42

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.neuro42.ai/

Last Round

Strategic

Aug 15, 2024

Total Funding Raised

$12.8M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

neuro42 is a medical technology company that develops a portable MRI, robotics, and artificial intelligence platform for the diagnosis and treatment of neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical Devices, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

portable MRIneurosurgical roboticsintraoperative imagingimage-guided surgerymedical roboticsmagnetic resonance imagingMRIsurgical roboticspoint-of-care imagingAI-driven medical imagingsurgical navigationmedtechrobotic surgeryneurosurgery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

neuro42 Comparables

Compare neuro42 with similar companies based on industry and business-model similarity.

neuro42 comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AiM Medical Robotics
89%
Synaptive Medical
86%
Wellumio
79%

neuro42 Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicAug 15, 2024
VC RoundJun 10, 2024
AngelMay 2, 2024
GrantSep 29, 2023
Series AJul 27, 2021
Seed
Jan 1, 2021

Key People

Founding team and executive leadership

Nikhil Sadhwani

Chief Development Officer Co-Founder

Founding Team

Amit Vohra

Founder & CEO

Founding Team

neuro42 Investors

Notable investors and investment history

neuro42 investors
InvestorRounds
NIH RADxGrant
Zynext VenturesStrategic
ShangBay CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 68% MoM.

  • Sep 29, 2023

    $5M grant awarded by NIH RADx

neuro42 Filings

Explore SEC and related filing metadata, where available.

neuro42 filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about neuro42's valuation, stock price, and market status.

Is neuro42 a public or private company?

neuro42 is a private company.

What is the current stock price of neuro42?

neuro42 is a private company with no public stock price. No recent secondary market data is available.

How much is neuro42 worth (valuation)?

Valuation information for neuro42 is not publicly available.

Can I buy neuro42 stock?

neuro42 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was neuro42's last funding round?

neuro42's most recent funding round was Strategic on August 15, 2024.

Who are the main investors in neuro42?

Key investors in neuro42 include Zynext Ventures.

Will neuro42 IPO soon?

No public IPO plans have been announced for neuro42.

How can I track neuro42 secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor neuro42's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range20
Year Founded2020
Last FundingAug 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?